Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Apr 4, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2021-11-01

Reporting Person: Floyd Robert Michael (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-31	Common Stock	G	7000	—	Disposed	70930	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Restricted Stock Units	$0	A	4286	Acquired		Common Stock (4286)	Direct
2022-03-31	Restricted Stock Units	$0	A	10715	Acquired		Common Stock (10715)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	66345	Indirect

Footnotes

F1: Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in an transaction exempt from Section 16 reporting.

F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.